PCM
ADVM

Penserra Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Penserra Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-225
Closed -$4K – 1348
2021
Q3 		$4K Buy
225
+2
+0.9% +$51 ﹤0.01% 1419
2021
Q2 		$7K Buy
223
+2
+0.9% +$108 ﹤0.01% 1293
2021
Q1 		$21K Sell
221
-3
-1% -$360 ﹤0.01% 964
2020
Q4 		$24K Buy
224
+143
+177% +$17.7K ﹤0.01% 825
2020
Q3 		$8K Buy
+81
New +$12.1K ﹤0.01% 830

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Penserra Capital Management's ADVM Position: Q4 2021 in Review

Penserra Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2021, closing a stake of 225 shares — an estimated $4K sold.

Penserra Capital Management first reported a position in ADVM in Q3 2020 and held it in 5 quarters. The position peaked at $24K in Q4 2020. 98 funds tracked by Wall St. Rank hold ADVM as of Q4 2021.

  • Penserra Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 225 Adverum Biotechnologies shares in Q4 2021, an estimated $4K.
  • Penserra Capital Management first reported a position in Adverum Biotechnologies in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Adverum Biotechnologies position peaked at $24K in Q4 2020.
  • 98 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.